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Background: Effective interventions to reduce HIV incidence in sub-Saharan Africa are urgently needed. Mathematical
modelling and the HIV Prevention Trials Network (HPTN) 052 trial results suggest that universal HIV testing combined
with immediate antiretroviral treatment (ART) should substantially reduce incidence and may eliminate HIV as a public
health problem. We describe the rationale and design of a trial to evaluate this hypothesis.
Methods/Design: A rigorously-designed trial of universal testing and treatment (UTT) interventions is needed because:
i) it is unknown whether these interventions can be delivered to scale with adequate uptake; ii) there are many
uncertainties in the models such that the population-level impact of these interventions is unknown; and ii) there are
potential adverse effects including sexual risk disinhibition, HIV-related stigma, over-burdening of health systems, poor
adherence, toxicity, and drug resistance.
In the HPTN 071 (PopART) trial, 21 communities in Zambia and South Africa (total population 1.2 m) will be randomly
allocated to three arms. Arm A will receive the full PopART combination HIV prevention package including annual
home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART
for those testing HIV-positive; Arm B will receive the full package except that ART initiation will follow current national
guidelines; Arm C will receive standard of care. A Population Cohort of 2,500 adults will be randomly selected in each
community and followed for 3 years to measure the primary outcome of HIV incidence. Based on model projections,
the trial will be well-powered to detect predicted effects on HIV incidence and secondary outcomes.
Discussion: Trial results, combined with modelling and cost data, will provide short-term and long-term estimates of
cost-effectiveness of UTT interventions. Importantly, the three-arm design will enable assessment of how much could
be achieved by optimal delivery of current policies and the costs and benefits of extending this to UTT.
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The global health burden associated with HIV infection
continues to grow, with an estimated 34 million people
living with HIV, including 23.5 million adults and children
in sub-Saharan Africa [1]. While several countries have
reported reductions in HIV prevalence and incidence,
prevalence remains extremely high, especially in Southern
Africa which continues to experience severe, generalized
epidemics with persistently high rates of HIV incidence [1].
While considerable progress has been made in expan-
ding the coverage of antiretroviral treatment (ART), a large
proportion of HIV-infected individuals who need treat-
ment are not yet receiving it. Worldwide, it is estimated
that 14.8 million adults and children are eligible for treat-
ment under current 2012 guidelines, of which 8 million are
receiving it [1]. ART is a lifelong commitment and there-
fore ongoing treatment costs continue to escalate as more
patients require ART. In sub-Saharan Africa, an estimated
2.3 million individuals have commenced ART during the
past two years, but during this same period there have
been approximately 3.6 million new infections [1]. Clearly,
unless the number of new infections can be steeply re-
duced, the number of individuals needing treatment will
continue to increase and it will be increasingly difficult and
costly to provide ART for all those who need it. Effective
HIV prevention thus remains a pressing priority in the era
of ART roll-out.
There is increasing recognition that a combination of
prevention methods will be needed to bring HIV transmis-
sion under effective control in the most severely affected
countries, and combination prevention programmes are
being developed to meet this need [2,3]. These may involve
the provision of proven prevention methods, such as male
circumcision [4-7] and prevention of mother-to-child
transmission (PMTCT) [8-12], a range of behavioural and
biomedical interventions specially targeted at those most at
risk of infection, and expanded testing and treatment for
individuals found to be HIV-infected [13,14]. The potential
role of earlier treatment as a preventive measure has been
emphasised by an individually randomised trial showing
that early treatment of HIV-infected individuals reduced
transmission to their sexual partners by 96% [15].
While combination prevention strategies are based on
sound epidemiological principles, they have not been ad-
equately evaluated in the field and there are no data on
their effectiveness or cost-effectiveness in reducing HIV
incidence at population level [16]. This paper describes the
rationale and design of a large-scale cluster-randomised
trial aimed at implementing a combination prevention
package including universal voluntary testing, active
linkage into care, and offer of immediate ART for all
those testing HIV-positive, and measuring its impact on
population-level HIV incidence. This study, the HIV
Prevention Trials Network (HPTN) 071 (PopART) trial,will be carried out in 21 communities in Zambia and
South Africa.
Approaches to HIV prevention in Africa
Since the principles of combination HIV prevention were
formulated, there has been new interest in the potential
impact of universal testing and treatment (UTT) interven-
tions. This concept represents a paradigm shift in HIV
prevention, since it focuses on identifying and intervening
in HIV-infected individuals in preference to the much lar-
ger uninfected population. Mathematical modelling has
indicated that if a high proportion of the population can
be tested, with those found to be HIV-infected offered im-
mediate ART, HIV infection could be reduced substan-
tially within two years and could potentially be eliminated
as a public health problem in the longer term [17-22], al-
though the model assumptions have been questioned
[23,24]. While challenging to deliver, this approach would
nevertheless have major advantages in terms of simplicity
and universality, potentially reducing the need for inter-
ventions targeting specific groups at high risk of infection,
who are often stigmatized, as well as bringing likely
clinical benefit to those infected with HIV.
Incident HIV infections necessarily result from trans-
mission of the virus between an HIV-infected index case
and an HIV-uninfected individual. HIV viral load is the
key determinant of viral transmission, as demonstrated
clearly in observational studies of sexual transmission
among HIV-discordant couples; in those studies, no
transmission was seen when the index case had a plasma
viral load below 1,000 copies HIV ribonucleic acid
(RNA)/mL [25,26]. By reducing plasma viral load to
undetectable levels (<50 copies HIV RNA/mL), it is as-
sumed that ART will also suppress viral burden in the
genital tract to levels at which transmission is unlikely to
occur [27,28], although genital shedding of HIV can
sometimes occur even when plasma viraemia is sup-
pressed [29]. While vertical HIV transmission occurs via
a different route, proof of concept is provided by trials
of PMTCT, which have demonstrated that HIV trans-
mission from mother to child before, during, or after de-
livery is largely prevented by ART [10-12].
Of greater relevance to sexual transmission are results
of the HPTN 052 trial. In this large, Phase III trial, the
effects of early ART on transmission were investigated in
1,763 HIV-serodiscordant couples [15]. HPTN 052 was
powered to determine the impact of immediate ART
initiation for the HIV-infected partner (at CD4 counts
between 350 and 550 cells/μL) on HIV transmission, com-
pared with ART initiation at CD4 counts ≤250 cells/μL.
The trial results were released early, after the early treat-
ment arm demonstrated a 96% reduction (hazard ratio
(HR): 0.04; 95% CI: 0.01–0.27; P <0.001) in HIV transmis-
sion to sexual partners, as well as significantly lower
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ART at CD4 counts above 550 cells/μL was not studied in
this trial, effects on HIV transmission would be expected
to be similar for any given baseline viral load if viral sup-
pression on treatment were achieved. Clinical benefits and
risks of starting ART at CD4 counts above 550 cells/μL
will be measured in the Strategic timing of AntiRetroviral
treatment (START) trial which is scheduled to report in
2015 [30]. However, given that relatively few patients from
Africa are included in this trial, the generalizability of its
findings for sub-Saharan Africa may be limited [31].
Recent observational data from a large population-based
cohort in South Africa have shown that the risk of HIV
acquisition is inversely proportional to the local coverage
of ART [32], providing additional evidence of the potential
effectiveness of treatment as prevention even at lower
ART initiation thresholds.
The full benefit of expanded provision of ART at
population level cannot be achieved while a large pro-
portion of the population are not aware of their HIV sta-
tus, and where those diagnosed HIV-positive are not
effectively linked to treatment and care services [33,34].
The UTT strategy aims to maximize the effects of ART
on transmission and morbidity by promoting universal
voluntary HIV testing throughout the community re-
peated at frequent intervals to detect new infections as
they occur, effective linkage to care, and the offer of im-
mediate onset of ART irrespective of CD4 count.
In the PopART intervention, universal testing will be
promoted and provided through a house-to-house cam-
paign delivered by specially trained community health
workers known as CHiPs (community HIV care pro-
viders). There is now considerable experience from simi-
lar campaigns in different parts of sub-Saharan Africa,
which have mostly achieved high rates of uptake and
acceptability. A recent systematic review showed an
overall average uptake of 83% and, importantly, showed
similar uptake in men and women [34], whereas male
clients are often under-represented at venue-based HIV
testing services [35].
UTTconstitutes a non-discriminatory approach whereby
testing is offered community-wide irrespective of per-
ceived risk of HIV infection and, on testing HIV-positive,
everyone is offered ART irrespective of immune status.
The resultant potential for normalisation of HIV could re-
duce stigma and have the added benefit of simplifying
HIV-care services, for both patients and providers.
UTT as part of combination prevention
Delivery of UTT is readily incorporated into a combin-
ation prevention package including other proven HIV pre-
ventive methods. Behaviour change messages have been
central to most AIDS control programmes in Africa, and
changes to safer sexual behaviour are assumed to havecontributed to the reductions in HIV prevalence in
Uganda, Zimbabwe, and other countries [36,37]. However,
there is a dearth of evidence from rigorously-designed
trials on what specific behavioural interventions bring
about the required behavioural changes leading to a
reduction in HIV incidence [38]. Similarly, while HIV
counselling and testing provide the gateway to key treat-
ment and prevention services, evidence of their effects on
behaviour and HIV risk is inconclusive [39-41]. Recent
findings on the population-level effects of expanded HIV
testing and counselling from the HPTN 043 trial point to-
wards a small reduction in HIV incidence in communities
randomised to receive community mobilization, mobile
voluntary counselling and testing, and post-test support
services (HR: 0.86; 95% CI: 0.73–1.02; P = 0.08), compared
to communities with standard voluntary counselling and
testing services alone [42].
In contrast, stronger evidence of effectiveness is avail-
able for some biomedical interventions. Male circumci-
sion was shown to reduce HIV incidence by around 60%
in three trials in Kenya, South Africa, and Uganda [5-7].
Safe services for medical male circumcision have been
recommended for wide-scale roll-out by the World
Health Organization (WHO) and the United Nations
Programme on HIV/AIDS (UNAIDS), although pro-
gress in implementation in many countries has been
slow [43,44]. HIV transmission is known to be facili-
tated by other sexually transmitted infections (STIs)
[45]. One trial in Tanzania showed that improved STI
treatment services reduced HIV incidence in the general
population, although other trials of a variety of STI inter-
ventions in different epidemiological settings have failed
to show an impact on HIV incidence [46]. PMTCT
services have been shown to have a major impact on the
rate of vertical transmission from HIV-positive pregnant
women to their infants [10-12].
Why are trials of UTT needed?
There is a very strong biological and epidemiological ra-
tionale for the potential efficacy of universal HIV testing
combined with immediate onset of ART. Many countries
and agencies are promoting wider delivery and uptake of
HIV testing in the community with the aim of ensuring
that all adults know their HIV status [47-50]. There is in-
creasing recognition of the potential value of starting ART
earlier, both for individual clinical benefit and to prevent
onward transmission, and international and national treat-
ment guidelines have moved steadily towards higher CD4
thresholds [51-54]. In the USA, many clinicians are
already prescribing ART for many of their HIV-positive
patients at CD4 counts well in excess of 500 cells/μL.
Some mathematical models have demonstrated that if
UTT can be delivered with high coverage, HIV incidence
could be reduced substantially [18-20,22].
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and the pressing public health need, UTT interventions
should be implemented immediately without the need
for supporting trials. We argue that rigorously designed
trials are needed for several cogent reasons [16].
First, it is not known whether UTT interventions can be
implemented on a large-scale in resource-poor settings and
whether they can achieve high uptake and acceptability. To
achieve high impact, such interventions will need to achieve
high coverage of HIV testing, which needs to be repeated at
frequent intervals. Those diagnosed HIV-positive need to
be effectively and rapidly linked to HIV treatment and care
services and to be started on ART without delay. Patients
started on ART also need to maintain high levels of ad-
herence in order to ensure effective viral suppression over a
prolonged time period. Interventions may fail at one or
more of these three critical stages.
Second, while findings from mathematical models are
encouraging, such models by necessity make numerous
assumptions, some of which are insufficiently supported
by empirical data. The initial models of UTT, showing
substantial effect sizes, have been criticised for over-
optimistic assumptions. Other modelling groups, using
different approaches and assumptions, have produced a
wide range of projections, although most of these agree
in suggesting substantial impact [22].
Third, while the results of the HPTN 052 study show
convincing evidence of effects on transmission in indi-
vidual partnerships in a clinical trial setting, the popula-
tion level impact of UTT is unknown [15]. It could be
much smaller because routinely provided interventions
may not achieve sufficiently high levels of uptake and
adherence. Conversely, there may be additional indirect
effects if there is high coverage of the intervention at
population level. The net benefits are very difficult to as-
sess convincingly without an empirical study.
Fourth, and importantly, there are many potential ad-
verse effects of large-scale UTT interventions. They will
require effective health educational messages that alter the
perception that ART is reserved for those who are sick
and emphasise that ART is now intended for all HIV-
infected individuals, the majority of whom will not have
any indication of disease. Where this messaging is not
achieved, ambivalence to ART could be anticipated. This
could be accompanied by low levels of ART adherence,
leading to the development of drug resistance. Associated
with this risk, there is also the potential for increased
transmission of resistant viruses as well as the need for
more expensive or toxic second-line regimens. Uncertain-
ties remain around the risks and benefits of prescribing
life-long treatment to healthy individuals with high CD4
counts. The widespread provision of ART may lead to
sexual risk disinhibition among either treated individuals
or the general population, resulting in higher incidence ofHIV and offsetting the protective effects of the interven-
tion. While the universal approach to testing and care
enshrined in UTT is designed to reduce HIV-related
stigma, possible harm through involuntary disclosure of
HIV status and other social harms cannot be ruled out.
Finally, health services in many endemic countries are
already struggling under the burden of providing care with
the current restricted approach to ART delivery. There is
genuine concern that more than doubling the number of
patients on ART may severely over-stretch clinic re-
sources, leading to a decline in the quality of care for HIV
and other health conditions.
A rigorously designed trial will provide clear evidence
of the balance of risks and benefits, and reliable esti-
mates of the effectiveness and cost-effectiveness of the
UTT strategy in reducing HIV incidence at population
level. Such evidence would likely be of great value to
policy makers in the study countries, other parts of sub-
Saharan Africa and globally.
Design
Overall design of HPTN 071 (PopART) trial
HPTN 071 (PopART) will measure the impact of the
PopART combination prevention intervention package on
HIV incidence at population level by means of a cluster-
randomised trial in Zambia and South Africa. The trial
will be carried out in 21 study clusters – 12 in Zambia
and 9 in South Africa. A cluster will be defined as the
catchment population of a government primary health
care facility which provides ART services to the popula-
tion in the community.
There will be three study arms with 7 clusters in each
arm:
Arm A: Clusters in this arm will receive the full
PopART combination prevention package including im-
mediate offer of ART, irrespective of CD4 count, for all
adults diagnosed with HIV infection.
Arm B: Clusters in this arm will receive the full
PopART package except that ART will be provided
according to current national treatment guidelines
(i.e., current CD4 threshold of 350 cells/μL in both
countries).
Arm C: Clusters in this arm will continue to receive
the current standard of care provided in these
communities.
The primary outcome, HIV incidence, will be mea-
sured in a randomly selected Population Cohort in all 21
clusters. The overall study design is summarised in
Figure 1. The full study protocol is available online [55],
but key components are summarised below.
Components of intervention in Arms A and B
The full PopART combination prevention package will
include the following components:
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offered to all residents: home-based visits will be
repeated at annual intervals, and all those without a
prior HIV-positive diagnosis will be encouraged to
re-test each year. The home-based testing service
will be carried out by the CHiP team that will also
support other components of the package.
 Linkage to care: those diagnosed HIV-positive
will be referred to the local primary health facility
for HIV treatment and care. The CHiPs will be
responsible for ensuring effective linkage to care,
and will follow-up HIV positive individuals who
have not presented at the clinic for care within a
defined period.
 Male circumcision: the CHiPs will also encourage
men who test HIV-negative and who are
uncircumcised to present to locally available
services for voluntary medical male circumcision.
 Condom promotion: during the household visits, the
CHiP team will provide behavioural risk reductionFigure 1 Summary of trial design.counselling and will offer a supply of condoms. Free
condoms will also be available at the local health
facilities and in the communities.
 Screening for symptoms suggestive of tuberculosis
(TB) and sexually transmitted infections, with
referral to the local health care facility for
appropriate further management as necessary.
 PMTCT: the CHiP team will identify any women
who are pregnant and encourage them to present
for antenatal care through the local health services.
Pregnant women who are diagnosed HIV-positive
will be encouraged to access PMTCT services. In
Arm A, all HIV-positive women will be offered
immediate ART irrespective of their CD4 status.
 HIV treatment and care: all HIV-positive individuals
will be encouraged to register for HIV treatment
and care at the local primary health care facility. In
Arm A, ART will be offered immediately to all
HIV-infected adults, irrespective of CD4 count,
while in Arm B, ART will be initiated according to
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other opportunistic infections will be provided
according to national guidelines. Clinical follow-up
and monitoring will be provided according to
standard clinic procedures, with additional
adherence support from the CHiP teams or other
community health workers.
Aside from the implementation of immediate ART in
Arm A, any changes to national treatment guidelines
over the duration of the trial will be adhered to in all
communities.
Arm C clusters will continue to receive the current
standard of care, and the CHiP services described above
will not be delivered in these communities.
CHiP teams
As described above, home-based testing and referral for
services will be carried out by a cadre of staff designated
as community HIV care providers (CHiPs). A CHiP is a
member of the community, appointed to provide a pack-
age of basic services at the household level. CHiPs will
work in pairs, in gender-balanced teams, and will have
been recruited with several requirements in mind. They
will have to be at least 18 years of age; have adequate rea-
ding and writing skills; be able to speak, read, and write in
English and be conversant with local languages; be able to
record data using an electronic data capture device; be
trained and licensed in HIV counselling (including child,
couple, family counselling) and testing (Zambia) or receive
training after employment (South Africa); be willing to
undertake training according to national or study require-
ments for community health worker staff (training in
psychosocial counselling, HIV counselling and testing,
adherence counselling, good clinical practice, and basic
knowledge of HIV and TB prevention, treatment, and
care); and be conversant with the local geography. They
will also have to be physically able and willing to walk long
distances; be able to maintain client confidentiality; and
preferably reside in the community of the PopART inter-
vention. Previous experience as a community health care
worker and prior experience in basic counselling, HIV psy-
chosocial counselling and testing, and adherence counsel-
ling will be desirable. People living openly with HIV in the
community and other HIV advocates will be welcomed.
The ratio of CHiPs to household members varies by
community depending on the density of households and
other local factors. Over 700 CHiPs will be deployed
across the 14 communities of Arms A and B in both
countries.
Study population
This study will be carried out in areas of Zambia and
South Africa that are known to have high HIV prevalenceand incidence and are continuing to experience severe
generalized HIV epidemics, with prevalence levels of 15%
to 20% in many communities. National estimates of HIV
prevalence in adults aged 15 to 49 are 13.5% for Zambia
and 17.8% for South Africa, and incidence estimates are
1.06% [56] and 1.49% [57], respectively.
The 21 study communities are shown in Figure 2. The
Zambia South Africa TB and AIDS Reduction (ZAMSTAR)
cluster-randomised trial [58] was previously carried out in
the same or nearby communities. The HPTN 071
(PopART) trial will benefit from the strong community and
stakeholder relations built up during the ZAMSTAR trial,
as well as epidemiological data on HIV and TB that have
been used to aid the design of the current trial.
Additional considerations that informed the selection
of the 21 communities for the current study were:
 They are as far as possible geographically distinct.
 No other major HIV prevention studies are planned
or ongoing.
 There is an adequate population size to minimize
the effects of contamination on outcome
measurements due to contact with other
communities or residents of other communities.
 Community willingness to be involved in the
current trial.
Key characteristics of the study communities are sum-
marised in Table 1. For 14 trial communities, these data
were available from the 2010 TB prevalence survey of
the ZAMSTAR trial, while for seven Western Cape com-
munities estimates were obtained from routine data, or
data from neighbouring ZAMSTAR trial communities.
Total population size (all ages) ranges from 21,386 to
166,251 with an average of 57,828 (66,864 in Zambia,
45,780 in South Africa). The three largest communities,
with populations exceeding 120,000, are all suburbs of
the capital city (Lusaka) in Zambia. The total population
of all 21 communities is approximately 1.2 million, based
on 2001 and 2011 census data for Zambian and Western
Cape communities, respectively, and this will include ap-
proximately 800,000 in the 14 intervention communities.
Adult HIV prevalence ranges from about 11% to 25%,
with an average of around 15% to 17% in both countries.
The proportion of HIV-infected adults on ART is more
variable and ranges from 13% to 38%, averaging around
25% in Zambia in 2012 and 30% in South Africa in 2012.
The prevalence of male circumcision is much higher in
the communities in South Africa (>50%) than in Zambia
(8–21%) as shown in Table 1.
Randomisation
Randomisation was carried out at public ceremonies
held simultaneously in Zambia and South Africa in
Figure 2 Map showing location of study communities.
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grouped into 7 matched triplets, 4 in Zambia and 3 in
South Africa, based on geographical proximity, imple-
menting partners for HIV services and the best available
estimates of adult HIV prevalence. The matched design
was used with the aim of minimizing between-community
variance in baseline HIV incidence, which is assumed to
be correlated with baseline HIV prevalence. With a re-
quirement to match on geographical area, implementing
partners for HIV service provision, and HIV prevalence, it
was not possible to match simultaneously on estimated
uptake of ART among HIV-positive individuals or cluster
size. It is acknowledged that this may increase somewhat
the variability in effect size across triplets. However, re-
stricted randomisation will help to ensure good balance in
average ART uptake and cluster size across trial arms A,
B, and C, as explained below.
After dividing the 21 clusters into 7 matched triplets
(Figure 2), allocation to the three study arms was carried
out using a process of restricted randomisation. This pro-
cedure was used to ensure overall balance across study
arms on cluster size, current ART uptake, and HIV preva-
lence. There were (3!)7 = 279,936 possible ways of allocat-
ing the clusters to the three study arms within matchedtriplets. These allocations were evaluated against balance
criteria to determine a restricted list of allocations that
achieve adequate balance on the three variables defined
above. The final allocation was selected randomly from
this restricted list of balanced allocations. These methods
were based on randomisation procedures used success-
fully in the ZAMSTAR trial [58].
Evaluation of impact
While the interventions will be delivered to the total
population of each intervention community (average
population size 57,828), the primary outcome of HIV in-
cidence and a range of secondary outcomes and process
measures will be obtained through a Population Cohort.
This cohort will consist of a random sample of 2,500
adults in each community (52,500 individuals in total)
who will be surveyed at baseline and then again after 12,
24, and 36 months. The baseline survey will take place
at roughly the same time as intervention delivery com-
mences in the same community. The impact of the in-
terventions will be measured by comparison of study
outcomes across the three study arms in the Population
Cohort during the 36 month follow-up period, rather
than through before-and-after comparisons.
Table 1 Characteristics of study communities
Country Triplet Community number Adult HIV prevalence (%)1 HIV-infected on ART (%)2 Population size3 Men circumcised (%)
Zambia 1 1 16 23 42,898 16
1 2 13 29 33,297 17
1 3 17 15 38,081 7
2 4 19 30 60,222 17
2 5 17 18 45,234 12
2 6 19 32 34,623 8
3 7 16 13 129,221 8
3 8 15 22 166,251 8
3 9 16 25 124,284 19
4 10 25 24 31,629 14
4 11 18 27 55,011 21
4 12 16 38 41,615 14
South Africa 5 13 19 35 34,096 87
5 14 19 35 21,386 Data unavailable
5 15 19 35 38,059 Data unavailable
6 16 15 37 72,544 Data unavailable
6 17 18 28 37,084 Data unavailable
6 18 14 36 44,821 53
7 19 11 25 36,009 Data unavailable
7 20 11 25 82,953 Data unavailable
7 21 12 18 45,067 Data unavailable
1Estimated from ZAMSTAR 2010 TB/HIV prevalence survey, for all Zambian communities, with age standardisation to the age structure of prevalence survey
participants and assuming 50% of the adult population are men. For Western Cape communities, source of HIV prevalence data varies by triplet. For Triplet 5,
community 13 was included in the ZAMSTAR trial and the ZAMSTAR 2010 TB/HIV prevalence survey data are used, as for Zambia. HIV prevalence is then assumed
to be the same in communities 14 and 15. For communities 16, 17, 19, 20, and 21, sub-district level data on antenatal clinic (ANC) prevalence were used, with the
assumption that adult HIV prevalence is 80% of the ANC prevalence value. Community 18 was included in the ZAMSTAR trial and the ZAMSTAR 2010 TB/HIV
prevalence survey data are used.
2Estimated from ZAMSTAR 2010 TB/HIV prevalence survey data, for all Zambian communities. The number of HIV-positive adults among prevalence survey participants
was estimated, separately for men and women, as the age-standardised HIV prevalence multiplied by the number of survey participants. The proportion of HIV-positive
individuals on ART was then calculated as (number self-reported on ART)/(estimated number of HIV-positive survey participants), and assuming that 50% of the adult
population are men. For Western Cape communities, data were used from October 2012 on (a) the number of individuals aged >15 years old on ART – measured either
at community or sub-district level, (b) population size among individuals >15 years old – measured using census data either at community or sub-district level, and
(c) HIV prevalence estimates. The number of HIV-positive individuals aged >15 years old was estimated as HIV prevalence × community (or sub-district) population size.
The proportion of HIV-positive individuals on ART was then calculated as (number of individuals >15 years old on ART)/(estimated number of HIV-positive individuals
aged >15 years old).
3Population size – for Zambia, based on 2001 census data; for Western Cape, based on 2011 census data.
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census will be completed in all trial communities, pro-
viding a map and listing of all households, and including
a count of the number of adults and children in each
household. The household listing will be used to select a
random sample of households which will be visited over
a 6 to 9 month period. During the visit to a selected
household, all household members will be enumerated
and a random number generator will be used to select
one adult resident aged 18 to 44 years. Following in-
formed consent, the randomly selected adult will be
invited to join the Population Cohort if they satisfy eligi-
bility criteria, in particular with respect to residency in
the community and an intention to remain resident for
the next 3 years.Only one adult will be randomly selected for the Popu-
lation Cohort from each randomly selected household.
This is to avoid the distortion of the trial results which
might occur if whole households or several members of a
household were to be evaluated, since this would in itself
constitute a mass testing and counselling intervention. In
particular, it is likely that many of the HIV-infected
spouses and regular partners of Population Cohort mem-
bers would be diagnosed and treated, thus reducing HIV
transmission in all three study arms. The statistical ana-
lysis will take into account the different sampling pro-
babilities resulting from the selection of one individual
irrespective of household size. The eligible age-range of 18
to 44 years was chosen because adults aged 18 years and
over are able to provide their own consent to participate
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are expected to occur in the 18 to 44 group based on past
data from these populations, and because HIV incidence
among adults aged 45 years or older is much lower than
among younger adults.
On enrolment and during each annual follow-up of the
Population Cohort, participants will be asked to complete
an interviewer-administered questionnaire covering socio-
demographic information and a wide range of behavioural
and HIV-related variables. At the end of the interview,
blood specimens will be taken and transported to study
laboratories for testing. All Population Cohort participants
will also be offered on-the-spot voluntary counselling and
testing using rapid HIV test kits. All HIV-infected indi-
viduals (those testing positive on the rapid test as well as
those who are already aware of their positive status) will
be referred to a health centre for further management.
Additional secondary outcomes and process measures
will be measured in the Population Cohort or through
data collected routinely by the health services or CHiP
teams, as described below.
Study outcomes
The primary outcome will be HIV incidence during
36 months of follow-up measured through prospective
follow-up of the Population Cohort.
The wide range of secondary outcomes include:
 HIV incidence over each of the first, second, and
third years of follow-up in the Population Cohort to
track if the impact on population-level incidence
increases over time.
 Community viral load* will be estimated by carrying
out HIV viral load testing of a random sample of
75 HIV-infected members of the Population Cohort in
each community at the baseline, 12-month and
36-month surveys, and all HIV-infected members
(estimated as about 300 per community) at the
24-month survey. Various measures of community
viral load, reflecting average viral load across the
population, have been proposed as potential
surrogate markers of the population-level success of
interventions involving ART for prevention [59,60].
 ART adherence and viral suppression*: HIV viral loads
of members of the Population Cohort who commence
ART after the start of the trial will be measured at the
24 month survey (see above). Viral load testing of all
HIV-infected participants in this survey will provide
adequate data on viral suppression in patients who
have been on ART for periods of 12–24 months.
Self-reported adherence in these patients will also be
analysed. Further data on loss to follow-up, treatment
adherence, and viral suppression will also be obtained
from health service data. ART drug resistance* will be measured at 24 months in
members of the Population Cohort who are not virally
suppressed, followed by back-testing of their baseline
and 12-month specimens, to assess the incidence of
acquired resistance among those commencing ARTafter
the start of the trial. ART drug resistance will also be
measured among members of the Population Cohort
with incident infection during follow-up to assess the
incidence of transmitted resistance.
 HIV disease progression, retention in care, death, and
ART toxicity: these outcomes will be measured both
in members of the Population Cohort and in the
wider population using routine health service data.
 Sexual risk behaviour will be measured in the
Population Cohort at each survey and used to assess
whether there is behavioural disinhibition related to
the intervention. This analysis will be supported by
data collected in the Population Cohort on Herpes
simplex virus, type 2 incidence, which has been
shown to be a biomarker for sexual risk behaviour
especially among young people [61-63].
 HIV-related stigma will be assessed through analysis
of self-reported data in the Population Cohort as
well as through qualitative research (see below).
 Case notification rates of TB and TB mortality
among these cases will be assessed through routine
health service data. TB case rates may be influenced
by higher levels of ART in the intervention arms
and by active case finding by the CHiP teams.
* Funding for these investigations is pending.
Process measures
Several process measures will be recorded in all three
study arms to evaluate the implementation and delivery
of the PopART interventions. These measures evaluate
processes that are intermediary between the provision of
the intervention and achievement of the primary out-
come, and will therefore be of value in understanding
the results of the trial as well as learning lessons for fu-
ture implementation of the intervention package.
Each of the following measures will be estimated using
a combination of data from the Population Cohort, the
CHiP teams, and routine health centre data:
 Uptake of HIV testing and re-testing.
 Time between HIV diagnosis and initiation of care.
 Uptake of ART screening and initiation of treatment.
 Uptake of services for PMTCT.
 Uptake of medical male circumcision.
Case–control studies
Three nested case–control studies will be carried out to
examine factors related to uptake of different compo-
nents of the PopART intervention.
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testing during the first round of home-based testing. Cases
will be those who refuse testing by the CHiP team and
controls will be those who accept testing, excluding those
already known to be HIV-infected. A random sample of
400 cases and 400 controls will be chosen from the study
communities in Arms A and B, and standardized ques-
tionnaires will be used to collect data on sexual and health
seeking behaviour, previous HIV testing, as well as stigma
and psycho-social questions. Cases and controls will also
have separate sections in the questionnaire, to explore rea-
sons for not testing and motivation to test, respectively.
The second case–control study will examine linkage to
care and initiation of ART and will be carried out in
Arm A only. Cases and controls will be selected from
those identified as HIV-positive by the CHiP teams and
who are not already taking ART. Cases will be those
who have not presented for care and initiated ART
within 3 months, and controls will be those who do ini-
tiate ART within this time-frame. A random sample of
400 cases and 400 controls will be chosen from the
study communities in Arm A.
Finally, the third case–control study will examine up-
take of HIV testing during the second round of home-
based testing in the second year of the intervention,
using similar methods to those for the first case–control
study.
Qualitative research
Qualitative studies will be conducted alongside the trial
in both Zambia and South Africa to provide important
contextual data and a more in-depth exploration of
community response to the PopART intervention. These
studies will include:
 Preliminary formative research in all 21 study
communities using participatory rapid appraisal
tools. This research was carried out to rapidly
collect background information on salient features
of each community, including geographical, cultural,
socio-economic, and health-related characteristics.
Information was also collected on the HIV
landscape of each community, including attitudes
and perceptions towards HIV, existing provision of
preventive and treatment services, and key
stakeholders. Findings from these surveys have
been used to prepare a descriptive account of each
community which can be used by the study team
and implementing partners to inform the delivery of
the intervention and research activities.
 Evaluation of the acceptability of the intervention:
research will be carried out in study communities in
Arms A and B at intervals during the trial to
examine the response of the community over timeto the different components of the intervention.
A mix of methods will be used, including
fieldworker structured diaries, in-depth interviews,
focus group discussions, structured observation, and
participatory rapid appraisal tools. Data will be
collected from local stakeholders, CHiP teams, and
community members from different age and gender
groups. Research on the process of community
engagement, and on how to ensure that research is
carried out in accordance with ethical guidelines,
will also be embedded in this work.
 Longitudinal study: a representative sample of cases
and controls from the first case–control study will
be recruited to this study and will be invited to give
in-depth interviews at three-monthly intervals until
the end of the trial. This study in Arms A and B
will complement the findings of the case–control
studies, and will document the longitudinal
trajectory of individual behaviour in relation to
uptake of HIV services.
 An ethnographic study, conducted in selected
communities in Arms A and C, will provide
contextual understanding of how communities
experience the roll-out of the PopART combination
prevention interventions. This research will also
examine a range of related issues including
HIV-related stigma, the role of welfare and food
security, sexual risk disinhibition, alcohol and drug
use, male circumcision, and the influence of different
stakeholders and social networks.
Mathematical modelling and economic evaluation
The design of the trial is benefiting from support from
the mathematical modelling team. The initial modelling
work provided estimates of projected impact over dif-
ferent time-scales and informed the sample size cal-
culations for the trial, as discussed below. During the
conduct of the trial, a more sophisticated stochastic
model of HIV transmission will be developed and fitted
to data from the trial, routine data, and published
sources to address several objectives.
 To help interpret the results of the trial: Process
data showing the extent of uptake of the
intervention compared with similar data from the
control arm will be used to obtain model projections
of expected impact under these conditions. By
examining projected impact under the conditions
prevailing in Zambia and South Africa, and in
different trial communities, we will be able to
examine whether the level of impact and variations
in impact are in accordance with expectations.
 To project longer-term impact: The trial will
measure the impact of PopART interventions over a
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during the trial will be used to project the likely
impact over longer time periods.
 To explore likely impact in different settings: If the
trial demonstrates impact, it is likely that similar
interventions will be implemented in a wide range of
settings. Therefore, the model will be used to
explore how impact would be expected to vary
depending on epidemiological, demographic, and
other characteristics of populations, and thus to
project likely impact in a range of settings.
 To explore the likely impact of alternative
intervention packages: Our study design will provide
empirical data on the impact of the specific packages
of preventive interventions incorporated in the
PopART programme. However, the model can be
used to explore the effect of adding or removing
components. For example, we can project the
impact of an intervention in which male
circumcision is not promoted, or where the
threshold for starting ART is set at different levels.
To optimise the value of the trial for health policy deve-
lopment, it is important that data are collected on cost and
cost-effectiveness as well as effectiveness. The economic
evaluation will assess the incremental health benefits of the
PopART intervention in relation to its incremental costs,
which will be estimated by comparing health services
utilisation and associated costs between the three study
arms. The main focus will be on costs to the health ser-
vices including equipment, materials, and personnel. The
economic evaluation will rely mainly on data on health sta-
tus and health service usage collected from the Population
Cohort, together with health facility data.
Benefits will be assessed in terms of lifetime change in
quality adjusted life years (QALYs) and/or disability ad-
justed life years (DALYs). By combining cost data with im-
pact estimates from the trial and model projections, it will
be possible to derive estimates of cost per QALY and/or
DALY using different time horizons. We will also be able
to explore the projected cost-effectiveness of alternative
prevention packages.
Statistical considerations
Intervention targets
The trial design has been guided by the results of mathe-
matical modelling. The preliminary PopART model is de-
scribed in a related paper [64] and was fitted to routine
HIV data from Zambia and South Africa, as well as data
from the ZAMSTAR trial which was carried out in the
same study areas. The model was used to explore the pro-
jected impact of the PopART interventions at different
levels of coverage, and this informed the choice of inter-
vention targets.Based on this work, Table 2 shows two sets of interven-
tion targets, a central target and an optimistic target, for
four key coverage indices. These include a target of 70%
to 75% annual coverage of the test and treat campaign,
which means that 70% to 75% of HIV-positive individuals
not already on ART would be diagnosed, linked to care,
and started on ART within 3 months. Other targets are to
keep the annual rate of treatment failure or drop-out
below 10% among those on ART; effectiveness of 90% to
95% of ART in blocking HIV transmission to sexual part-
ners; and 50% uptake of male circumcision among HIV-
negative men who are not already circumcised. Based on
these intervention targets, Table 2 shows the projected im-
pact on HIV incidence in Arms A and B compared with
Arm C in each country and over different time periods.
The projections assume that the intervention is rolled
out over a 6 month period during each annual round. In
Zambia, for example, if the central targets are achieved
for each aspect of the intervention, then, over 3 years of
follow-up, HIV incidence in Arm A is expected to be
61% lower than HIV incidence in Arm C, whereas it will
be 25% lower in Arm B than in Arm C. For example, if
HIV incidence in Arm C is 1 per 100 person-years – it
will be reduced to 0.39 per 100 person-years in Arm A.
If, on the other hand, the intervention achieves the opti-
mistic targets when rolled out, then HIV incidence will
be reduced by 63% in Arm A and 27% in Arm B when
compared with Arm C. These projections vary little ac-
cording to the assumed level of HIV incidence in Arm
C, and so are not very sensitive to background trends in
incidence. The projections indicate that the predicted
impact over 3 years is 61% to 64% in Arm A and 25% to
27% in Arm B. Impact is substantially higher in Years 2
and 3, as expected. As a sensitivity analysis, assuming
roll-out takes 12 rather than 6 months, projected impact
over three years is 58% to 61% for Arm A and 24% to
26% for Arm B (data not shown – see related paper for
details) [64].
The coverage of the test and treat intervention is es-
sentially the product of two parameters – the proportion
of the population that accepts HIV testing and the pro-
portion of those testing HIV positive who link to care
and initiate treatment when eligible. The sensitivity of
the projected impact on the primary outcome (reduction
in HIV incidence over 3 years) to variation in these key
uptake measures has been assessed (with low and high
values of 40% to 95% for each of parameter); a strong
linear relationship was found [64]. It will therefore be
possible to update our projections once process data on
uptake are available.
Sample size
The primary outcome will be the incidence of HIV infec-
tion measured among initially HIV-uninfected members
Table 2 Parameter values assumed for the model of the impact of the intervention for central and optimistic target
scenarios, and projected impact on HIV incidence in Arms A and B compared with Arm C, assuming intervention
roll-out over a 6-month time period
Parameter Central target Optimistic target
Annual coverage of test and treat campaign 70% 75%
Treatment failure & drop-out rate, per year 10% 10%
Effectiveness of ART in blocking transmission 90% 95%
Take up of male circumcision when offered 50% 50%
Arm A Arm B Arm A Arm B
Zambia Impact on cumulative incidence (3 years) 61% 25% 63% 27%
Impact on cumulative incidence (first 2 years) 58% 24% 61% 25%
Impact on HIV incidence during Year 1 51% 20% 54% 21%
Impact on HIV incidence during Year 2 65% 27% 67% 28%
Impact on HIV incidence during Year 3 67% 29% 68% 30%
South Africa Impact on cumulative incidence (3 years) 62% 26% 64% 27%
Impact on cumulative incidence (first 2 years) 59% 25% 61% 26%
Impact on HIV incidence during Year 1 52% 22% 55% 23%
Impact on HIV incidence during Year 2 65% 28% 67% 29%
Impact on HIV incidence during Year 3 68% 29% 69% 30%
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36 months. Based on national estimates of HIV incidence
and on HIV prevalence in the chosen study areas, it is
expected that HIV incidence in the control arm will be in
the range 1.0 to 1.5/100 py. With a matched study design,
and based on estimates of between-community variation
from the ZAMSTAR trial in the same study areas, it is
expected that the between-community coefficient of va-
riation will be in the range 0.15 to 0.20. Seven communi-
ties were chosen per study arm and a Population Cohort
of 2,500 adults per community to attain adequate power
to detect a difference in incidence between Arms A and C
(reflecting the full impact of the intervention), as well as
the difference in intervention effect between Arms A and
B (reflecting the additional effect of immediate HIV treat-
ment compared with current national guidelines) [65,66].
Table 3 shows that the study will be very well powered
to detect an effect of 35% or larger in Arm A or Arm B
compared with Arm C, and moderately well powered to
detect an effect of 30% under favourable assumptions.
For the direct comparison of Arms A and B, Table 4
shows that the study will be well powered to detect a
difference between effects of 60% and 30%, 55% and
25%, and 50% and 20%. Tables 3 and 4 allow for a base-
line HIV prevalence of 15% and assume losses to follow-
up of 20% over two years, and 25% over three years.
Although there is considerable variation in the popula-
tion size of the 21 study communities (Table 1), a con-
stant sample size was used for the Population Cohort in
each community to maximize statistical efficiency [67].
A sample of 2,500 adults will ensure that the PopulationCohort never exceeds 25% of the total adult population.
Restricting the size of the cohort relative to the total
population helps to minimise the Hawthorne effect of
following the cohort on HIV transmission in the wider
community.
Sample size calculations for secondary outcomes are
presented in the full study protocol [55].
Ethical considerations
Risks and benefits
The mathematical modelling projections indicate that, if
the interventions can be implemented as planned with
high levels of coverage, there should be a substantial
reduction in HIV incidence in Arms A and B compared
with Arm C. The results of the HPTN 052 trial and
other studies also suggest that there will be some clinical
benefit for HIV-positive individuals who commence
ART at higher CD4 counts, although clinical effects in
those with CD4 counts above 550 cells/μL have not
yet been established. Concomitant effects on TB and
mother-to-child transmission of HIV are also expected
and there may be a reduction in HIV-related stigma as a
result of the universal approach to HIV control intrinsic
to the PopART interventions.
However, some adverse effects may also be anticipated
and are summarised above in the section on ‘Why trials
of UTT are needed’. The wide range of potential risks
and benefits mandates a rigorously conducted trial to
weigh up these effects and to determine whether the ef-
fectiveness and cost-effectiveness of the interventions
would merit wider scale implementation.
Table 3 Power for comparison of HIV incidence in Arm A or
B with Arm C, with 7 communities per arm and Population
Cohort of 2,500 adults per community (assuming that on
average 2,125 (85%) will be HIV-uninfected at baseline
and that loss to follow-up will be 20% after 2 years and
25% after 3 years) with 5,206 person-years per
community over 36 months
HIV incidence
rate/100 py
(control arm)
Between-cluster
coefficient of
variation (k)
Effectiveness (%) Power (%)
1.0 0.15 25% 57%
1.0 0.15 30% 74%
1.0 0.15 35% 87%
1.0 0.15 40% 95%
1.0 0.15 45% 99%
1.0 0.15 50% 100%
1.0 0.15 55% 100%
1.0 0.15 60% 100%
1.0 0.15 65% 100%
1.0 0.20 25% 44%
1.0 0.20 30% 60%
1.0 0.20 35% 75%
1.0 0.20 40% 87%
1.0 0.20 45% 94%
1.0 0.20 50% 98%
1.0 0.20 55% 99%
1.0 0.20 60% 100%
1.0 0.20 65% 100%
1.5 0.15 25% 64%
1.5 0.15 30% 81%
1.5 0.15 35% 92%
1.5 0.15 40% 98%
1.5 0.15 45% 100%
1.5 0.15 50% 100%
1.5 0.15 55% 100%
1.5 0.15 60% 100%
1.5 0.15 65% 100%
1.5 0.20 25% 48%
1.5 0.20 30% 65%
1.5 0.20 35% 80%
1.5 0.20 40% 91%
1.5 0.20 45% 96%
1.5 0.20 50% 99%
1.5 0.20 55% 100%
1.5 0.20 60% 100%
1.5 0.20 65% 100%
Table 4 Power for comparison of HIV incidence between
Arms A and B, with 7 communities per arm and Population
Cohort of 2,500 adults per community (assuming that on
average 2,125 (85%) will be HIV-uninfected at baseline
and that loss to follow-up will be 20% after 2 years and
25% after 3 years)
HIV
incidence
rate/100 py
(control arm)
Between-
cluster
coefficient of
variation (k)
Effectiveness
(%)
Arm A
Effectiveness
(%)
Arm B
Power
(%)
1.0 0.15 50% 20% 89%
1.0 0.15 50% 25% 78%
1.0 0.15 55% 25% 92%
1.0 0.15 55% 30% 82%
1.0 0.15 60% 25% 98%
1.0 0.15 60% 30% 94%
1.0 0.15 65% 25% 99%
1.0 0.15 65% 30% 99%
1.0 0.20 50% 20% 78%
1.0 0.20 50% 25% 65%
1.0 0.20 55% 25% 83%
1.0 0.20 55% 30% 71%
1.0 0.20 60% 25% 93%
1.0 0.20 60% 30% 87%
1.0 0.20 65% 25% 98%
1.0 0.20 65% 30% 96%
1.5 0.15 50% 20% 94%
1.5 0.15 50% 25% 86%
1.5 0.15 55% 25% 96%
1.5 0.15 55% 30% 90%
1.5 0.15 60% 25% 99%
1.5 0.15 60% 30% 98%
1.0 0.20 65% 25% 99%
1.0 0.20 65% 30% 99%
1.5 0.20 50% 20% 84%
1.5 0.20 50% 25% 72%
1.5 0.20 55% 25% 88%
1.5 0.20 55% 30% 78%
1.5 0.20 60% 25% 96%
1.5 0.20 60% 30% 92%
1.0 0.20 65% 25% 99%
1.0 0.20 65% 30% 98%
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The main aspect of the intervention that goes beyond
current guidelines is the offer of immediate commence-
ment of ART regardless of CD4 count or clinical stage in
Arm A. Written informed consent will be obtained from
patients in this arm who are offered immediate treatment
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prevailing national treatment guidelines. Any patients
declining this offer will be provided with follow-up and
treatment in the same health facilities according to
current standard of care.
Written informed consent will be obtained before enrol-
ling individuals in the Population Cohort and case–
control studies. Written informed consent will also be
required of individuals participating in qualitative research
activities that involve collection of participant-identified
responses to interviewer questions (such as interviews and
focus groups).
The activities of the CHiP team are poised between an
established public health intervention (home-based testing
and outreach) and a public health research project (data
collection and additional follow-up). Household members
will be asked to give their verbal consent for participation
in this community intervention, which will also permit
data collected by CHiPs to be used in aggregate form for
research purposes. Individuals will be asked to provide
written informed consent for HIV testing as is done rou-
tinely at health facilities. In addition, a written information
leaflet will be provided to all households.
Full ethical review of the trial protocol has been carried
out by the ethics committees of the University of Zambia,
Stellenbosch University, London School of Hygiene and
Tropical Medicine and the US Centers for Disease
Control and Prevention.
Discussion
Both South Africa and Zambia have seen a recent de-
crease in the incidence of new HIV infections. However,
HIV incidence remains at very high levels and, while it is
encouraging that ART reduces mortality, prevalence
continues to increase as HIV-infected patients survive
for longer [56,57]. Unless more intensive prevention
measures can be applied, there will be a continuously
expanding number of HIV-infected individuals requiring
lifelong treatment, and it will be many years before the
epidemic is finally brought under effective control and
HIV infection is eliminated as a public health problem.
Two approaches to intensive HIV control are now being
explored by public health researchers. Combination pre-
vention acknowledges that single interventions are
unlikely to be sufficient to reverse the epidemic while
packages that combine a range of proven interventions
are more likely to be effective [2,3]. UTT is a new para-
digm whereby population-wide HIV testing is combined
with effective linkage to care and immediate onset of ART
with the aim of maintaining the health of HIV-infected in-
dividuals and steeply reducing HIV transmission [68]. The
PopART intervention, which includes promotion of male
circumcision and other proven interventions as well as
UTT, combines these two approaches. A further trial inKwaZulu Natal, South Africa, is also seeking to estimate
the effect of ART initiated immediately after HIV diagno-
sis, irrespective of CD4 count, on the incidence of new
HIV infections in the general population over a period of
24 months [69]. Alternative approaches are being investi-
gated in other studies. For example, a trial in Botswana
will measure the impact of a strategy combining universal
testing with initiation of ART on the basis of HIV viral
load as well as CD4 count [70].
The HPTN 071 (PopART) trial in Zambia and South
Africa will use a rigorous study design to obtain robust
measures of the effectiveness and cost-effectiveness of
the intervention in reducing HIV incidence. It will also
measure effects on a wide range of important secondary
outcomes, including a detailed assessment of potential
adverse effects.
The trial has a number of important limitations. First,
modelling projections show that the impact of the inter-
vention is expected to build up over time, due to the time
needed to achieve full coverage and for the indirect “herd
protection” effects of a population-wide intervention on
HIV transmission to come into play. The trial will only
measure effects for up to 36 months and may therefore
underestimate longer-term impact. However, the mathe-
matical models fitted to the trial data will provide long-
term projections of effectiveness. Second, the trial will
measure the impact of the package of interventions rather
than individual components. However, the comparison of
Arm A with Arm B will provide information on the
additional impact of immediate ART over and above the
effect of delivering current interventions with high cover-
age. Also, the mathematical modelling will allow us to
explore the projected effects of different combinations of
interventions. Third, there may be some contamination
effects due to migration, travel, and sexual contacts across
community boundaries. We have tried to minimise these
effects by choosing large communities with an average
population of around 60,000, but this contamination will
lead to some dilution of measured impact. Fourth, attri-
tion in the Population Cohort will lead to some selection
bias in our estimate of HIV incidence, so every effort will
be made to retain and track Population Cohort partici-
pants to minimise the effect of selection bias on effect es-
timates. Finally, measures of intervention uptake in the
Population Cohort may be biased by Hawthorne effects
due to repeated follow-up of the cohort over 3 years, in-
cluding the offer of rapid HIV testing and referral to the
clinic for HIV care. This is why we will also collect process
data on uptake using data collected by CHiP teams and
from health facilities. We will also seek funding for a final
Population Cross-Sectional Survey in which Hawthorne
effects can be avoided.
The central target for the annual coverage of the test
and treat campaign is 70%, as shown in Table 2. We
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one of the reasons why it is important to carry out the
trial to see whether it can be achieved in practice. A sys-
tematic review and meta-analysis of home-based testing
in sub-Saharan Africa has shown that uptake of home-
based testing is high with an overall estimate of 83% ac-
ceptance of HIV testing among individuals offered a test,
rising to 90% or more in several more recent studies
[34]. We believe that the intensity of our intervention –
with a team of two CHiPs for every 350 households and
several attempts to contact individuals at home to offer
HIV testing, followed by active referral to care for HIV-
infected individuals combined with strengthened ART
services at the clinic – should bring the above target
within reach.
UTT not only holds promise for prevention of HIV
transmission but also provides impetus for treatment
scale-up, thereby reducing morbidity and mortality in
HIV-infected individuals. If the trial is completed success-
fully, the results will provide valuable information on the
feasibility, acceptability, and impact of this ambitious
population-wide intervention strategy which will inform
health policy not only in Zambia and South Africa, but in
many other countries with generalised HIV epidemics
[16,71]. Our hope is that, if the trial results are encou-
raging, this new paradigm for HIV control may prove the
decisive turning point for this destructive and costly
epidemic.Trial status
Enrolling.
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